Table 2.
Baseline characteristics.
| AGAMENON-HER2 training cohort | Christie hospital cohort | |
|---|---|---|
| N (%) | N (%) | |
| Age, median (range) | 65 (22–87) | 67 (27–85) |
| Sex, male | 510 (77.9) | 70 (84.3) |
| HER2+ | ||
| IHC 3+ | 470 (71.8) | 54 (65.0) |
| IHC 2+ and FISH+ | 184 (28.1) | 29 (34.9) |
| ECOG PS | ||
| 0 | 158 (24.1) | 25 (30.1) |
| 1 | 396 (60.5) | 42 (50.6) |
| 2 | 91 (13.9) | 15 (18.0) |
| 3 | 0 | 1 (1.2) |
| Lauren subtype | ||
| Intestinal | 393 (60.0) | 59 (71.0) |
| Diffuse | 95 (14.5) | 16 (19.2) |
| Mixed | 33 (5.0) | – |
| Not available | 124 (18.9) | 8 (9.6) |
| Signet-ring cells | 85 (12.9) | 5 (6.0) |
| Histological grade | ||
| 1 | 124 (18.9) | – |
| 2 | 219 (33.4) | 42 (50.60) |
| 3 | 164 (25.0) | 28 (33.7) |
| Not available | 138 (21.1) | 13 (15.6) |
| Surgery of primary tumour | 116 (17.7) | 9 (10.8) |
| Primary tumour site | ||
| Oesophagus | 88 (13.4) | 21 (25.3) |
| Stomach | 421 (64.3) | 18 (21.6) |
| GEJ | 136 (20.7) | 44 (53.0) |
| Number of metastatic sites (organs involved), >2 | 194 (29.6) | 30 (36.4) |
| Site of metastases | ||
| Peritoneum | 196 (29.9) | 11 (13.2) |
| Lung | 153 (23.3) | 21 (25.3) |
| Liver | 352 (53.8) | 37 (44.5) |
| Ascites | 93 (14.2) | 1 (1.2) |
| Bone | 61 (9.3) | 10 (12.0) |
| Non-regional lymph nodes | 329 (50.3) | 40 (48.1) |
| Liver tumour burden | ||
| No | 290 (44.3) | 46 (55.4) |
| <25% | 168 (25.6) | 25 (30.1) |
| 25–50% | 98 (14.9) | 10 (12.0) |
| 51–75% | 64 (9.7) | 2 (2.4) |
| >75% | 25 (3.8) | – |
| Overall tumour burden | ||
| Low | 82 (12.5) | 17 (20.4) |
| Moderate | 116 (17.7) | 22 (26.5) |
| High | 190 (29.0) | 33 (39.7) |
| Very high | 266 (40.6) | 11 (13.2) |
| CEA, median (range) | 9.5 (0–36001) | |
| Albumin | ||
| Normal (>35 g/dL) | 429 (65.5) | 79 (95.1) |
| 30–35 g/dL | 100 (15.2) | 3 (3.6) |
| <30 g/dL | 54 (8.2) | 1 (1.2) |
| Not available | 62 (9.4) | – |
| NLR, median (range) | 3.4 (0.1–29.3) | 4.3 (1.2–42.2) |
| Chemotherapy regimens | ||
| Anthracycline-based triplets | 28 (4.2) | 0 |
| Carboplatin–5-fluorouracil | 32 (4.8) | 0 |
| Carboplatin–capecitabine | 0 | 5 (6.0) |
| Cisplatin–5-fluorouracil | 92 (14.0) | 0 |
| Docetaxel-containing regimens | 15 (2.2) | 0 |
| FOLFOX | 110 (16.8) | 0 |
| Other | 18 (2.7) | 1 (1.2) |
| CAPOX | 191 (29.2) | 0 |
| XP | 168 (25.6) | 77 (92.7) |
| Total | 654 (100) | 83 (100) |
The criteria for overall tumour burden are specified in Table 1.
CAPOX, capecitabine/oxaliplatin; CEA, carcinoembryonic antigen; FOLFOX, 5-fluorouracil/oxaliplatin; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; N, number of patients; NLR, neutrophil-to-lymphocyte ratio; XP, capecitabine/cisplatin.